Skip to main content

Table 2 Joint effect survival analysis of ODAD2- rs7893462 (AG vs. AA + GG) and clinical parameters in Guangxi HBV-related HCC OS

From: Outer dynein arm docking complex subunit 2 polymorphism rs7893462 modulates hepatocellular carcinoma susceptibility and can serve as an overall survival biomarker for hepatitis B virus-related hepatocellular carcinoma after hepatectomy: a cohort study with a long-term follow-up

Groups

Variables

Genotype

Patients(n = 468)

MST(months)

Crude HR (95% CI)

Crude P

Adjusted HR (95% CI)

Adjusted P

 

Radical resectiona

rs7893462

      

1

Yes

AG

106

42

1

 

1

 

2

No

AG

100

34

1.303 (0.906–1.875)

0.154

1.039 (0.695–1.555)

0.851

3

Yes

AA + GG

155

84

0.558 (0.385–0.808)

0.002

0.591 (0.397–0.881)

0.01

4

No

AA + GG

98

80

0.698 (0.472–1.034)

0.073

0.468 (0.300–0.731)

0.001

 

Tumor size

       

I

≤ 5 cm

AG

77

50

1

 

1

 

II

> 5 cm

AG

135

28

1.754 (1.168–2.632)

0.007

1.557 (0.993–2.441)

0.054

III

≤ 5 cm

AA + GG

112

123

0.449 (0.270–0.747)

0.002

0.418 (0.240–0.727)

0.002

IV

> 5 cm

AA + GG

144

61

1.125 (0.740–1.711)

0.581

0.879 (0.555–1.393)

0.584

 

Tumor number

       

a

Single

AG

156

42

1

 

1

 

b

Multiple

AG

56

23

1.930 (1.321–2.820)

0.001

1.536 (0.901–2.618)

0.115

c

Single

AA + GG

190

95

0.608 (0.440–0.841)

0.003

0.592 (0.417–0.841)

0.003

d

Multiple

AA + GG

66

75

0.750 (0.490–1.149)

0.187

0.610 (0.353–1.056)

0.077

 

BCLC

       

A

A

AG

115

74

1

 

1

 

B

B

AG

34

27

2.010 (1.228–3.290)

0.005

1.575 (0.781–3.176)

0.204

C

C

AG

63

17

3.500 (2.331–5.254)

< 0.0001

3.037 (1.539–5.991)

0.001

D

A

AA + GG

162

101

0.634 (0.424–0.946)

0.026

0.647 (0.422–0.992)

0.046

E

B

AA + GG

40

75

0.925 (0.524–1.632)

0.788

0.706 (0.342–1.455)

0.345

F

C

AA + GG

54

34

1.906 (1.220–2.978)

0.005

1.296 (0.656–2.560)

0.455

 

Portal vein tumor thrombusb

       

i

No

AG

166

47

1

 

1

 

ii

Yes

AG

45

14

3.598 (2.428–5.332)

< 0.0001

1.432 (0.762–2.692)

0.365

iii

No

AA + GG

217

95

0.570 (0.415–0.782)

0.0005

0.543 (0.387–0.761)

0.0004

iv

Yes

AA + GG

39

27

1.727 (1.102–2.706)

0.017

0.664 (0.335–1.314)

0.24

 

Serum AFPc

       

AA

AFP ≤ 400 (ng/mL)

AG

108

41

1

 

1

 

BB

AFP > 400 (ng/mL)

AG

86

27

1.463 (1.004–2.131)

0.047

1.327 (0.900–1.957)

0.154

CC

AFP ≤ 400 (ng/mL)

AA + GG

133

84

0.518 (0.350–0.766)

0.001

0.589 (0.395–0.878)

0.009

DD

AFP > 400 (ng/mL)

AA + GG

107

80

0.675 (0.456–0.9996)

0.0498

0.604 (0.405–0.902)

0.014

  1. Abbreviation: HBV hepatitis B virus, HCC hepatocellular carcinoma, HR hazard ratio, CI confidence interval, MST median survival time, OS overall survival, BCLC Barcelona Clinic Liver Cancer, AFP α-fetoprotein, NA not available, ODAD2 outer dynein arm docking complex subunit 2
  2. aInformation of radical resection was unavailable in 9 patients
  3. bInformation of PVTT was unavailable in 1 patient
  4. cInformation of AFP was unavailable in 34 patients
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us